The invention relates to protein-based T-cell receptor knockdown, and its use in T-cell therapies.

Transgenic microalgae expressing at least one exogenous biologically active protein. The protein-expressing microalgae are used for the oral delivery of the biologically active protein to the target organism in its intact and functional form. The exogenous protein, expressed in algae, is characterized by being biologically active, exerting at least one specific activity having a beneficial effect on the subject consuming the algae. The transgenic microalgae are used as animal food for aquatic or land animals welfare or as food supplement for human healthcare.

The invention relates to protein-based T-cell receptor knockdown, and its use in T-cell therapies.

Thermothelomyces heterothallica (formerly Myceliophthora thermophila) genetically modified to produce glycoproteins with N-glycans of mammalian proteins (particularly human, companion animal and other animal proteins) are provided, comprising deletion or disruption of the alg3 gene, expression of ER-targeted Mannosidase 1 (alpha-1.2-Mannosidase), and expression of ER-targeted Glucosidase 2 alpha-subunit. The Th. heterothallica may also further comprise heterologous GlcNAc transferase 1 (GNT1), GlcNAc transferase 2 (GNT2), STT3 subunit of a heterologous oligosaccharyltransferase and galactosyltransferase.

The invention relates to polypeptides containing a cytoplasmic domain ending with a MAST-2 binding domain, from 11 to 13 residues, the first two residues of which are S and W, and the last four residues of which are Q, T, R and L, the polypeptides presenting a high affinity for the PDZ domain of the human MAST2 protein. The invention also relates to polynucleotides, vectors, lentiviral particles, cells as well as compositions containing the same. The invention is also directed to the use of the polypeptides, polynucleotides, vectors, lentiviral particles, cells and compositions in the treatment and/or prevention of a disease, disorder or condition, which alters the Central Nervous System (CNS) and/or the Peripheral Nervous System (PNS). The invention also concerns molecular signatures of cellular genes to determine the neurosurvival and/or neuroprotection activity of a molecule.

The invention relates to protein-based T-cell receptor knockdown, and its use in T-cell therapies.

The present disclosure relates to fusion proteins for inducing immune response and treating cancer, and particularly to fusion proteins for use as an immunogenic enhancer for inducing humoral immune response and cell-mediated immune response.

The present disclosure provides immunomodulatory fusion proteins-metal hydroxide complexes comprising an immunomodulatory domain adsorbed to a metal hydroxide via ligand exchange. The disclosure also features compositions and methods of using the same, for example, to treat cancer.

T cells expressing a chimeric antigen receptor (CAR) targeting CD3 can be susceptible to fratricide because T cells express CD3 on their surface as part of the T cell receptor (TCR)/CD3 complex. To reduce fratricide, CD3 surface expression can be downregulated using an anti-CD3 antibody (e.g., an anti-CD3 single-chain antibody) coupled to an intracellular targeting signal such as an endoplasmic reticulum (ER) retention signal. Retention of CD3 in the ER can allow T cells expressing a CD3 CAR to grow in culture without compromising their cytotoxic activity against CD3 positive T cells. The T cells described herein can be particularly useful for treating T cell diseases (e.g., a disease caused by T cell defects or disorders). In addition, downregulating CD3 surface expression can reduce graft versus host disease when allogeneic T cells are introduced into a mammalian host.